Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Nevro Stock Bounded Higher on Thursday

By Cory Renauer – Nov 7, 2019 at 6:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A third-quarter earnings report that beat expectations lifted spirits and the medical-device stock.

What happened

Shares of Nevro (NVRO -0.55%), a medical device company with a focus on pain management, are soaring in response to a positive third-quarter earnings report. The company reported earnings and revenue that blew past analyst expectations, and raised guidance for the rest of 2019. As a result, the stock gained 21% on Thursday.

So what 

After the bell on Wednesday, Nevro told investors that third-quarter revenue reached $100.2 million, which was $7.9 million more than the average analyst was expecting. On the bottom line, the consensus estimate for earnings was a loss of $0.84, but the company narrowed its loss to just $0.58 per share. 

Very happy woman with her hands up in the air in a joyful way, standing in front of an upward sloping chart.

Image source: Getty Images.

In the U.S., both trial-run spinal cord stimulation procedures and permanent implant procedures rose by 18%, compared to the previous year. Strong procedure growth allowed Nevro to add some icing to its third-quarter earnings cake by boosting revenue expectations for 2019 to a range between $383 million and $386 million from a previously provided range between $368 million and $374 million.

Now what

At the moment, Nevro's proprietary high-frequency technology, called HF10, is driving spinal cord stimulation procedure growth because it doesn't cause the persistent buzzing sensation that previous generations of spinal cord stimulators are famous for. Also, HF10 systems don't need to be switched off when patients are sleeping or driving, and they're less likely to cause unexpected shocks in response to unusual movements.

Last year, the company was able to prevent Boston Scientific from launching a high-frequency product of its own. This July, a judge slapped an injunction on privately held Stimwave that will prevent its wirelessly powered injectible stimulators from using a high frequency, as well. 

Earlier this month, Nevro launched the Senza Omnia system for patients who want the best of both worlds. Senza Omnia is the first and only neurostimulator that can deliver all the usual low-frequencies and HF10. Although the company's still losing money, a monopoly on high-frequency stimulation devices could push this high-flying healthcare stock much higher.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nevro Stock Quote
Nevro
NVRO
$49.13 (-0.55%) $0.27
Boston Scientific Stock Quote
Boston Scientific
BSX
$41.30 (0.66%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.